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Summary
Background.  —  Current  guidelines  recommend  unfractionated  heparin  (UFH)  or  low-molecular-
weight heparin  plus  an  oral  anticoagulant  for  the  prevention  of  thromboembolism  in  patients
undergoing  electric  cardioversion  of  atrial  ﬁbrillation  (AF).  Selective  factor  Xa  inhibitors,  such
as fondaparinux,  which  has  a  favourable  beneﬁt-risk  proﬁle  in  the  prevention  and  treatment
of venous  thromboembolism  and  the  management  of  acute  coronary  syndromes,  have  not  been
systematically  evaluated  in  this  setting.
Aim.  —  To  evaluate  the  efﬁcacy  and  safety  of  fondaparinux  versus  standard  treatment  in
patients undergoing  echocardiographically-guided  cardioversion  of  AF.
Methods.  —  In  this  multicentre,  randomized,  open-label,  controlled,  two-parallel-group,  phase
II pilot  study,  patients  with  AF  undergoing  electric  cardioversion  following  transoesophageal
echocardiography  (TEE)  were  randomized  to  fondaparinux  or  standard  therapy  (UFH  plus  vitamin
K antagonist  [VKA]).  Patients  showing  an  atrial  thrombus  in  the  ﬁrst  TEE  (clot-positive)  were
randomized  to  treatment  with  fondaparinux  or  standard  care  for  4  weeks  before  cardioversion.
Results. —  The  primary  endpoint  (combined  rate  of  cerebral  neurological  events,  systemic
thromboembolism,  all-cause  death  and  major  bleeding  events)  occurred  in  3  of  174  (1.7%)
patients  on  fondaparinux  and  2  of  170  (1.2%)  patients  on  UFH  +  VKA.  The  rate  of  thrombus  dis-
appearance  among  clot-positive  patients  was  higher  in  the  fondaparinux  arm  (11  of  14;  78.6%)
than in  the  UFH  +  VKA  arm  (7  of  14;  50.0%).  Incidences  of  adverse  events  were  similar  (45.4%
with fondaparinux  and  46.5%  with  UFH  +  VKA).
Conclusion.  —  In  this  pilot  study  in  patients  with  TEE-guided  cardioversion,  the  use  of  fonda-
parinux appeared  to  be  well  tolerated,  with  similar  efﬁcacy  to  UFH  +  VKA.  Furthermore,  a  trend
to greater  thrombus  resolution  was  observed.
© 2015  Published  by  Elsevier  Masson  SAS.
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Résumé
Justiﬁcation.  —  Les  recommandations  actuelles  suggèrent  la  prescription  d’une  héparine  non
fractionnée  ou  une  héparine  de  bas  poids  moléculaire  et  un  traitement  anticoagulant  oral  au
décours aﬁn  de  prévenir  le  risque  thromboembolique  artériel  des  patients  en  ﬁbrillation  atriale
avec une  indication  à  une  cardioversion  électrique.  Les  inhibiteurs  sélectifs  du  facteur  Xa,  tels
le fondaparinux,  ont  un  proﬁl  bénéﬁce-risque  favorable  dans  la  prévention  et  le  traitement  de
la thrombose  veineuse  périphérique  et  dans  la  prise  en  charge  des  syndromes  coronaires  aigus,
mais n’ont  pas  été  évalués  dans  la  ﬁbrillation  atriale.
Objectifs.  —  Évaluer  l’efﬁcacité  et  la  sécurité  du  fondaparinux  versus  un  traitement  standard
chez les  patients  ayant  une  indication  à  une  cardioversion  électrique  d’une  ﬁbrillation  atriale
guidée par  échocardiographie  transœsophagienne.
Méthode.  — Cette  étude  randomisée,  multicentrique,  ouverte,  contrôlée  avec  deux  groupes
parallèles  est  une  étude  pilote  de  phase  II,  incluant  des  patients  en  ﬁbrillation  atriale,  ayant  une
indication  à  une  cardioversion  électrique  au  décours  d’une  échographie  transœsophagienne.  Ces
patients ont  été  randomisés  entre  un  groupe  fondaparinux  et  un  groupe  traitement  standard
(héparine  non  fractionnée  +  AVK).  Les  patients  ayant  un  thrombus  dans  l’oreillette  ou  l’auricule
gauche lors  de  la  première  échocardiographie  transœsophagienne  (groupe  clot  positive)  ont
été randomisés  pour  un  traitement  par  fondaparinux  ou  un  traitement  standard  4  semaines  au
décours de  la  cardioversion.
Résultats.  —  Le  critère  de  jugement  principal  (critère  combiné  événements  neurologiques
cérébrovasculaires,  embolie  artérielle  systémique,  décès  de  toute  cause  et  saignement  majeur)
est survenu  chez  3  des  174  patients,  (1,7  %)  du  groupe  fondaparinux  et  2  des  170  patients  (1,2  %
à des  patients  sous  héparine  non  fractionnée  +  AVK).  Le  taux  de  disparition  de  la  thrombose
atriale gauche  dans  le  groupe  clot  positive  était  plus  élevé  dans  le  fondaparinux  (11/14,  78,6  %)
versus 7/14,  50  %  dans  le  groupe  héparine  non  fractionnée  +  AVK.  L’incidence  des  événements
indésirables  était  similaire  dans  les  deux  groupes  (45,4  %  dans  le  groupe  fondaparinux,  45  %  dans
le groupe  héparine  non  fractionnée  +  AVK).
Conclusion.  —  Dans  cette  étude  pilote  de  cardioversion  guidée  par  ETO,  l’utilisation  de  fonda-
parinux apparaît  comme  bien  tolérée  avec  une  efﬁcacité  similaire  au  traitement  conventionnel
héparine non  fractionnée  +  AVK.  Une  tendance  à  un  taux  de  réduction  accru  de  la  thrombose
auriculaire  gauche  a  été  observée.
© 2015  Publié  par  Elsevier  Masson  SAS.
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ackground
lectrical  cardioversion  to  restore  sinus  rhythm  is  a  com-
on  procedure  for  patients  with  persistent  atrial  ﬁbrillation
AF).  In  patients  with  AF  lasting  >  2  days,  thromboem-
olic  events  have  been  reported  in  5—7%  of  those  who
ndergo  cardioversion  in  the  absence  of  anticoagulation
1—3].  The  occurrence  of  thromboembolism  is  related  to
oth  dislodgement  of  atrial  thrombi  and  post-cardioversion
eft  atrial  stunning  [4].  Transoesophageal  echocardiogra-
hy  (TEE)  offers  optimal  imaging  of  the  atria  and  allows
or  accurate  identiﬁcation  and  exclusion  of  thrombi  [5].
urthermore,  a  TEE-guided  approach  to  early  cardiover-
ion  of  AF  in  conjunction  with  periprocedural  therapeutic
nticoagulation  with  either  unfractionated  heparin  (UFH)  or
ow-molecular-weight  heparin  (LMWH)  has  a  similar  safety
roﬁle  to  conventional  anticoagulant  therapy  (i.e.  1  month
f  effective  oral  anticoagulation  before  cardioversion)  [6,7].
ence,  current  guidelines  for  the  management  of  AF  of  >  48
ours’  duration  recommend  ≥  3  weeks  of  efﬁcient  anticoag-
lation  with  an  oral  anticoagulant  (international  normalized
atio  [INR]  2.0—3.0)  before  cardioversion  followed  by  ≥  4
eeks  of  treatment  afterwards,  i.e.  the  ‘‘conventional
trategy’’  [8].  Alternatively,  a  TEE-guided  strategy  can  be
ollowed,  in  which  the  3-week  period  of  anticoagulation
an  be  shortened  if  TEE  reveals  no  left  atrial  or  left  atrial
ppendage  (LAA)  thrombus  or  sludge  [9—11].
The  use  of  UFH  requires  frequent  monitoring  and
ose  adjustment  of  anticoagulation  [7]  whereas  LMWH
apidly  achieves  adequate  anticoagulation  levels  and  does
ot  require  regular  anticoagulation  monitoring.  However,
noxaparin,  which  has  been  shown  to  be  non-inferior  to  UFH
n  patients  undergoing  TEE-guided  cardioversion  [7],  needs
o  be  administered  twice  daily.  In  contrast,  the  antithrom-
otic  fondaparinux  sodium  has  the  advantage  of  once-daily
pplication.  This  selective  factor  Xa  inhibitor  has  shown  a
avourable  beneﬁt-risk  proﬁle  in  trials  in  the  prevention
nd  treatment  of  venous  thromboembolism  and  in  the  man-
gement  of  acute  coronary  syndromes,  and  its  use  is  now
ecommended  in  evidence-based  guidelines  as  an  alterna-
ive  to  heparin  [12—14].  Furthermore,  fondaparinux  carries
 very  low  risk  of  thrombocytopoenia  [15].
The  aim  of  the  SAfety  of  Fondaparinux  in  transoe-
ophageal  echocardiography-guided  Electric  cardioversion
f  Atrial  Fibrillation  (SAFE-AF)  study  was  to  evaluate  the
fﬁcacy  and  safety  of  fondaparinux  versus  standard  ther-
py  (UFH  +  vitamin  K  antagonist  [VKA])  for  the  prevention  of
hromboembolic  complications,  death  and  major  bleeding
vents  in  patients  undergoing  cardioversion  of  non-valvular
F.
ethods
tudy design
AFE-AF  was  an  international,  multicentre,  randomized,
pen-label,  controlled,  two-parallel-group,  phase  II  pilot
tudy  to  evaluate  the  efﬁcacy  and  safety  of  fondaparinux
or  anticoagulation  of  patients  with  AF  undergoing  electri-
al  cardioversion  following  TEE  (Fig.  1).  After  stratiﬁcation
nto  clot-positive  and  clot-negative  patients  according  to  the
resence  or  absence  of  thrombus  in  the  left  atrial  cavity
f
s
a
fA.  Cohen  et  al.
r  LAA  on  TEE,  patients  were  randomized  to  receive  either
ondaparinux  or  UFH  followed  by  VKA.  The  TEE  scans  were
ssessed  by  the  treating  physicians.
In  the  fondaparinux  arm,  clot-negative  patients  received
ondaparinux  7.5  mg  once  daily  subcutaneously  (body
eight  <  100  kg)  or  10  mg  once  daily  (body  weight  >  100  kg)
or  the  ﬁrst  7—10  days  after  randomization,  followed  by  3
eeks  of  fondaparinux  2.5  mg  once  daily  until  day  28  ±  4.
lot-positive  patients  were  given  fondaparinux  5—10  mg,
epending  on  weight  and  renal  function,  for  28  ±  4  days.
n  patients  whose  second  TEE  showed  that  the  thrombi
ad  disappeared,  cardioversion  was  performed  and  the
atients  were  treated  in  the  same  manner  as  clot-negative
atients.
In  the  UFH  +  VKA  arm,  both  clot-negative  and  clot-
ositive  patients  received  an  initial  intravenous  bolus
njection  of  70  IU/kg  (≥  5000  IU)  of  UFH  followed  by  a  con-
inuous  infusion  with  an  initial  rate  of  15  IU/kg  per  hour.  The
nfusion  dose  was  adjusted  to  maintain  an  activated  partial
hromboplastin  time  at  1.5—2  times  the  reference  control
alue  and  was  continued  for  ≥  72  hours.  VKA  treatment  was
tarted  as  soon  as  possible  and  adjusted  to  achieve  a  target
NR  of  2—3.  In  clot-positive  patients,  TEE  was  repeated  after
8  days  and  cardioversion  was  performed  if  the  thrombi  had
isappeared.  Post-cardioversion  VKA  treatment  was  contin-
ed  for  28  days.
Clot-positive  patients  with  persistent  thrombi  at  the  sec-
nd  TEE  from  both  groups  were  excluded  from  the  study
xcept  for  follow-up  on  day  90  ±  7.
atients
ale  and  female  patients  aged  ≥  18  years  were  eligi-
le  to  participate  in  this  study  if  they  qualiﬁed  for
ardioversion  and  had  AF  meeting  at  least  one  of  the
ollowing  criteria:  acute  clinical  symptoms  (e.g.  palpi-
ations,  chest  pain,  dyspnoea,  fatigue,  light-headedness,
yncope)  for  ≥  48  hours  and  <  1 year  and  AF  recorded  on
 baseline  electrocardiogram;  newly  discovered  AF  per-
isting  for  ≥  7  days;  or  recurrent  AF  persisting  for  ≥  7
ays  and  <  1  year.  Key  exclusion  criteria  were:  duration
f  current  episode  of  AF  >  1  year;  acute  neurological
eﬁcit;  treatment  with  antithrombotic  agents  (including
ow-dose  anticoagulation  >  96  hours  before  randomization);
reatment  with  oral  non-steroidal  anti-inﬂammatory  drugs
r  aspirin  >  325  mg/day  for  >  72  hours  before  randomization;
reatment  with  two  antiplatelet  drugs;  active  and  clin-
cally  signiﬁcant  bleeding  within  the  past  month;  major
urgery  within  the  past  3  months;  uncontrolled  arterial
ypertension;  bacterial  endocarditis;  calculated  creatinine
learance  <  30  mL/min;  body  weight  <  50  kg,  and  planned
urgery  or  intervention  within  the  next  65  days.
The  study  was  conducted  in  accordance  with  all  appli-
able  regulatory  requirements,  with  the  principles  of  Good
linical  Practice,  all  applicable  patient  privacy  require-
ents  and  the  guiding  principles  of  the  Declaration
f  Helsinki,  including,  but  not  limited  to:  institutional
eview  board/independent  ethics  committee  review  and
avourable  opinion/approval  of  study  protocol  and  any  sub-
equent  amendments;  patient  written  informed  consent,
nd  investigator  reporting  requirements.  All  patients  were
ree  to  withdraw  from  the  study  at  any  point.
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Study endpoints
The  primary  objective  of  the  study  was  to  compare  subcu-
taneous  fondaparinux  with  UFH  +  VKA  with  respect  to  the
occurrence  of  the  primary  combined  endpoint  of  cerebral
neurological  events,  systemic  thromboembolism,  all-cause
death  and  major  bleeding  events  occurring  during  the  whole
treatment  period,  i.e.  from  randomization  to  4  days  after
the  last  administration  of  study  drug.  The  secondary  objec-
tives  of  the  study  were  to  compare,  up  to  day  90  ±  7,  the
effects  of  fondaparinux  versus  UFH  +  VKA  on  the  components
of  the  combined  endpoint,  thrombus  resolution,  alternative
bleeding  deﬁnitions  (please  see  below),  success  of  electrical
cardioversion  and  hospitalizations.
Major  bleeding  was  deﬁned  as  a  bleed  that  was  clinically
overt  and  at  least  one  of  the  following:  fatal;  symptomatic
intracranial,  retroperitoneal,  intraocular;  led  to  a  decrease
in  haemoglobin  of  ≥  3.0  g/dL  (with  each  blood  transfu-
sion  unit  counting  for  1.0  g/dL  of  haemoglobin)  or  required
transfusion  of  ≥  2  units  of  red  blood  cells.  Other  clinically
s
(
e
(utaneous; TEE: transoesophageal echocardiography; UFH: unfrac-
vert  bleeding  events  that  did  not  meet  the  criteria  for
ajor  bleeding  were  categorized  as  minor  bleeding.  Bleed-
ng  events  were  also  analysed  using  other  criteria,  as  deﬁned
n  the  following  studies:  Thrombolysis  in  Myocardial  Infarc-
ion  (TIMI)  [16]  and  Anticoagulation  in  Cardioversion  using
noxaparin  (ACE)  [7].
All  events  were  reviewed  by  an  independent  and  blinded
djudication  committee  (see  the  Appendix  A  for  details).
tatistical analysis
his  was  a  pilot  study  and  as  such  was  not  powered  to  enable
ormal  statistical  comparisons  between  randomized  treat-
ent  therapies  but  did  not  preclude  the  analysis  of  data
s  observed.  The  aim  was  to  randomize  approximately  350
atients  (175  per  treatment  group)  into  the  study.  With  this
ample  size,  the  half-width  of  the  95%  conﬁdence  interval
CI)  for  the  estimated  event  rate  (e.g.  for  the  primary
ndpoint  of  efﬁcacy)  was  at  most  3.3  percentage  points
absolute  width)  for  an  anticipated  event  rate  of  5%.  This
126  A.  Cohen  et  al.
Figure 2. Patient ﬂow chart. AE: adverse event; mITT: modiﬁed intention-to-treat; SAE: serious adverse event; TEE: transoesophageal
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Schocardiography; UFH: unfractionated heparin; VKA: vitamin K a
ndpoint discontinued due to an SAE.
ample  size  was  expected  to  provide  sufﬁcient  accuracy
o  describe  the  primary  endpoint  event  rate,  allowing  for
escriptive  between-group  comparisons  and  comparisons
ith  historical  data.
A  generalized  linear  model  stratiﬁed  according  to  the
bsence  or  presence  of  a  thrombus  during  ﬁrst  TEE  was
lanned  to  provide  an  adjusted  estimate  of  the  primary
ndpoint.  However,  the  adjusted  estimates  could  not  be  cal-
ulated  due  to  the  low  event  rate.  Thus,  the  unadjusted
vent  rates  (percentages  of  patients  with  an  event  in  each
reatment  group),  including  their  two-sided  95%  CIs  and  the
ifference  between  the  treatment  groups  with  the  associ-
ted  two-sided  95%  CIs  are  presented.
esultsatient disposition
he  study  was  conducted  in  34  European  study  centres  (see
he  Appendix  A  for  locations).  A  total  of  349  patients  were
I
p
a
anist. a One patient in the fondaparinux arm who met the primary
nrolled,  175  of  whom  were  randomized  to  fondaparinux
nd  174  to  standard  care  with  UFH  +  VKA.  One  patient  in  the
ondaparinux  group  did  not  receive  treatment  because  of  a
rohibited  medication,  and  four  patients  in  the  UFH  +  VKA
roup  withdrew  consent.  The  safety/modiﬁed  intention-to-
reat  (mITT)  population  therefore  comprised  174  patients
n  the  fondaparinux  group  (14  clot-positive  and  160  clot-
egative  at  ﬁrst  TEE)  and  170  in  the  UFH  +  VKA  group  (14
lot-positive  and  156  clot-negative  at  ﬁrst  TEE).  The  patient
ow  diagram  is  given  in  Fig.  2. Baseline  characteristics  and
chocardiographic  variables  were  similar  in  the  two  treat-
ent  groups  and  are  summarized  in  Tables  1—3.
tudy outcomesn  the  mITT  analysis,  the  primary  endpoint  occurred  in  three
atients  (1.7%,  95%  CI  0.4—5.0)  in  the  fondaparinux  arm
nd  in  two  patients  (1.2%,  95%  CI  0.1—4.2)  in  the  UFH  +  VKA
rm.  Table  4  provides  information  on  the  occurrence  of
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Table  1  Patient  baseline  characteristics.
Fondaparinux  (n  =  174)  UFH  +  VKA  (n  =  170)
Male  105  (60.3)  110  (64.7)
Age  (years)  68.2  ±  11.1  66.8  ±  11.9
Body  mass  index  (kg/m2)  29.3  ±  5.7  28.7  ±  5.8
Underlying  heart  disease
Arterial  hypertension  135  (77.6)  121  (71.2)
Heart  failure 30  (17.2) 43  (25.3)
Coronary  artery  disease 24  (13.8) 26  (15.3)
Duration  of  current  AF  episode  (days) 23.3 ±  53.3 18.4  ±  38.0
Most  frequent  symptoms  of  current  episode
Dyspnoea  100  (57.5)  108  (63.5)
Palpitations  88  (50.6)  84  (49.4)
Pattern  of  atrial  ﬁbrillation
Newly  discovered  138  (79.3)  124  (72.9)
Recurrent  36  (20.7)  46  (27.1)
Time  since  ﬁrst  AF  episode  (months)  52.0  ±  60.4  53.6  ±  76.4
Total  number  of  AF  episodesa 1  (1—100)  1  (1—105)
CHADS2 scoreb 1.6  ±  1.1  1.5  ±  1.1
CHA2DS2-VASc  scorec 2.4  ±  1.3  2.2  ±  1.3
Concomitant  antiarrhythmics  160  (92.0)  156  (91.8)
Concomitant  amiodarone  51  (29.3)  38  (22.4)
Data are mean ± standard deviation or number (%), unless otherwise stated. AF: atrial ﬁbrillation; UFH: unfractionated heparin; VKA:
vitamin K antagonist.
a Median (range).
b CHADS2 score = one point for each of C (congestive heart failure), H (hypertension), A (age ≥ 75 years), D (diabetes mellitus); two
points for S (history of stroke/transient ischaemic attack/thromboembolism).
c CHA2DS2-VASc score = 1 point for each of C (congestive heart failure), H (hypertension), D (diabetes mellitus), V (vascular disease),
A (age 65—74 years), Sc (sex category = female); two points for each of A (age ≥ 75 years) and S (history of stroke/transient ischaemic
attack/thromboembolism).
Table  2  Transthoracic  echocardiography.
Fondaparinux  (n  =  174)  UFH  +  VKA  (n  =  170)  P
LVEF  (%)a 54.9  ±  12.6  54.1  ±  13.0  0.60
Left  atrial  diameter  (mm)b 46.1  ±  8.3  45.2  ±  8.4  0.30
Any  mitral  valve  regurgitationc 110  (65.5)  95  (57.9)  0.18
Data are mean ± standard deviation or number (%). LVEF: left ventricular ejection fraction; UFH: unfractionated heparin; VKA: vitamin
K antagonist.
a Data available in 167 fondaparinux and 165 UFH + VKA patients.
b Data available in 165 fondaparinux and 161 UFH + VKA patients.
c Data available in 168 fondaparinux and 164 UFH + VKA patients.
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fthe  primary  endpoints.  All  of  the  events  were  in  clot-
negative  patients;  all  three  events  in  the  fondaparinux  arm
were  major  bleedings,  one  of  which  was  a  fatal  intracra-
nial  bleed.  In  this  patient,  post-treatment  cerebral  imaging
revealed  a  large  cerebral  tumour.  No  cases  of  major  bleeding
were  observed  in  clot-positive  patients  treated  with  fonda-
parinux.  In  the  UFH  +  VKA  arm,  one  major  bleed  and  one
cerebrovascular  event  occurred.
Table  5  details  the  results  of  the  components  of  the
composite  outcome  at  the  end  of  treatment  +  4  days  and
follow-up  (90  ±  7  days).  The  number  of  major  bleedings
remained  the  same  when  the  ACE  study  criteria  [7]  for  major
bleeding  were  applied.  However,  when  major  bleeding  was
w
s
dlassiﬁed  according  to  the  stricter  TIMI  criteria  [17],  there
ere  fewer  major  bleedings  in  both  arms:  one  in  the  fonda-
arinux  arm  and  none  in  the  UFH  +  VKA  arm.  Minor  bleeding
ccurred  in  three  patients  in  the  fondaparinux  arm  and  in
our  patients  in  the  UFH  +  VKA  arm  during  the  treatment
eriod.
Cardioversion  was  performed  in  151  of  174  (86.8%)
atients  in  the  fondaparinux  arm  and  148  of  170  (87.1%)
atients  in  the  UFH  +  VKA  arm.  Fifteen  patients  in  the
ondaparinux  arm  and  10  patients  in  the  UFH  +  VKA  arm
ere  in  sinus  rhythm  before  the  planned  cardioversion,
o  this  procedure  was  not  performed.  Cardioversion  was
eferred  due  to  the  presence  of  thrombi  in  28  patients.  The
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Table  3  Transoesophageal  echocardiography.
Fondaparinux  (n  = 174)  UFH  +  VKA  (n  =  170)
Thrombus  in  LAA  or  LA  14  (8.0)  14  (8.2)
LA  spontaneous  echocardiographic  contrast
Moderate  11  (6.3)  15  (8.8)
Severe  6  (3.4)  7  (4.1)
LAA  spontaneous  echocardiographic  contrast
Moderate  18  (10.3) 12  (7.1)
Severe  4  (2.3) 9  (5.3)
Sludge  2  (1.1)  2  (1.2)
Thrombus  size  (LAA),  maximum  diameter  (cm)a 1.1  ±  0.6  1.5  ±  0.5
Data are mean ± standard deviation or number (%). LA: left atrium; LAA: left atrial appendage; UFH: unfractionated heparin; VKA:
vitamin K antagonist.
a Data available in 10 fondaparinux and 9 UFH + VKA patients.
Table  4  Details  of  patients  who  met  the  primary  endpoint.
Treatment  group Clot  status Age  (years)  Event
Fondaparinux  Negative  87  Major  bleeding  (rectus  sheath/abdominal  wall  haematoma)
Fondaparinux  Negative  50  Major  bleeding  (intracranial)
Fondaparinux  Negative  86  Major  bleeding  (retroperitoneal)
UFH  +  VKA  Negative  93  Cerebral  event:  massive  stroke
UFH  +  VKA  Negative  81  Major  bleeding  (gastrointestinal)
UFH: unfractionated heparin; VKA: vitamin K antagonist.
p
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t
frimary  success  rate  of  electrical  cardioversion  was  sim-
lar  between  fondaparinux-treated  and  UFH  +  VKA-treated
atients  (90.7%  vs  89.9%;  P  =  0.85,  two-sided  Fisher’s  exact
est,  Table  6).  Sinus  rhythm  persisted  at  the  end  of
a
1
Table  5  Primary  and  secondary  endpoints  (modiﬁed  intention
Until  end  of  treatment  +  4  da
Fondaparinux
(n  =  174)
UFH/VKA
(n  =  170)
%
(
Primary  endpointa 3  (1.7)  2  (1.2)  0
(
Cerebral  neurological  events  0  1  (0.6)  —
(
Systemic  thromboembolism  0  0  0
All-cause  death  1  (0.6)  0  0
(
Major  bleeding  events  3  (1.7)  1  (0.6)  1
(
Minor  bleeding  events  3  (1.7)  4  (2.4)  —
(
Major  or  minor  bleeding  events  6  (3.4)  5  (2.9)  0
(
Data are number (%) unless otherwise stated. CI: conﬁdence interval; 
a Combined rate of cerebral neurological events, systemic thromboem
b P = 1.0 (Fisher’s exact test).ollow-up  (90  ±  7  days)  in  109  patients  in  the  fondaparinux
rm  and  in  111  patients  in  the  UFH  +  VKA  arm  (Table  6).
At  the  second  TEE,  left  atrial  thrombi  had  disappeared  in
1  of  14  (78.6%)  cases  in  the  fondaparinux  arm  and  in  7  of
-to-treat/safety  population).
ys  Until  follow-up  (90  ±  7  days)
 difference
95%  CI)
Fondaparinux
(n  =  174)
UFH/VKA
(n  =  170)
%  difference
(95%  CI)
.5
—2.0—3.1)b
6  (3.4)  2  (1.2)  2.3
(−0.9—5.4)
0.6
—1.7—0.6)
1 (0.6)  1  (0.6)  0 (−.6—1.6)
 0  0  0
.6
−0.5—1.7)
3 (1.7)  0  1.7
(−0.2—3.7)
.1
−1.1—3.4)
4 (2.3)  1  (0.6)  1.7
(−0.8—4.2)
0.6
−3.6—2.4)
4 (2.3)  5  (2.9)  −0.6
(−4.0—2.7)
.5
−3.2—4.2)
8 (4.6)  6  (3.5)  1.1
(−3.1—5.2)
UFH: unfractionated heparin; VKA: vitamin K antagonist.
bolism, all-cause death and major bleeding events.
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Table  6  Secondary  endpoints  (modiﬁed  intention-to-treat/safety  population).
Fondaparinux  (n  =  174)  UFH/VKA  (n  =  170)
Primary  successful  electrical  cardioversiona 137  (90.7)  133  (89.9)
Thrombus  in  LA/LAA  at  second  TEEb 3  (21.4)  7  (50.0)
Sinus  rhythm
At  end  of  treatment  114  (65.5)  119  (70.0)
At  follow-upc 109  (71.2)  111  (77.6)
Rehospitalization
Until  end  of  treatment  +  4  days 14  (8.0) 7 (4.1)
Until  follow-up 18  (10.3) 11  (6.5)
Data are number (%). LA: left atrium; LAA: left atrial appendage; TEE: transoesophageal echocardiography; UFH: unfractionated heparin;
VKA: svitamin K antagonist.
a Data available in 151 fondaparinux and 148 UFH + VKA patients.
b Among the 14 fondaparinux and 14 UFH + VKA patients with a clot at the ﬁrst TEE.
c Data available in 153 fondaparinux and 143 UFH + VKA patients.
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a14  (50.0%)  cases  in  the  UFH  +  VKA  arm  (odds  ratio  3.67,  95%
CI  0.70—19.12;  P  =  0.24,  Fisher’s  exact  test).
The  mean  duration  of  hospital  stay  was  5.9  ±  5.9  days  in
the  fondaparinux  arm  and  8.1  ±  4.1  days  in  the  UFH  +  VKA
arm  (P  <  0.001,  t  test).  Rehospitalization  occurred  in  18
(10.3%)  patients  treated  with  fondaparinux  and  in  11  (6.5%)
patients  treated  with  UFH  +  VKA  until  the  end  of  follow-up
(P  =  0.24,  Fisher’s  exact  test).
Safety results
The  incidences  of  treatment-emergent  adverse  events  were
similar  in  both  treatment  groups  (79  of  174  [45.4%]  in  the
fondaparinux  group  vs  79  of  170  [46.5%]  in  the  UFH  +  VKA
group),  with  recurrent  AF  being  the  most  frequently
reported.  Three  patients  (all  clot-negative  at  baseline  and
all  treated  with  fondaparinux)  died,  one  during  the  treat-
ment  phase  (haemorrhagic  shock  following  abdominal  wall
haematoma)  and  two  during  follow-up  (one  reported  as
‘‘sudden  death,  natural’’  and  one  intracranial  bleeding  in
the  presence  of  a  previously  undiagnosed  brain  tumour).
Discussion
The  results  of  our  pilot  study  show  that  TEE-guided  car-
dioversion  of  AF  using  the  selective  factor  Xa  inhibitor
fondaparinux  is  associated  with  low  rates  of  thromboem-
bolism  and  major  bleeding  and  resulted  in  numerically
similar  efﬁcacy/safety  event  rates  compared  with  the
UFH  +  VKA  treatment  arm.  Of  interest,  the  current  study
demonstrates,  for  the  ﬁrst  time,  that  fondaparinux  is  effec-
tive  for  dissolving  atrial  thrombi  before  cardioversion  in
patients  with  AF.
TEE-guided  direct  electrical  cardioversion  is  often  per-
formed  to  restore  sinus  rhythm  quickly  and  relieve  patients’
symptoms;  it  is  considered  a  safe  procedure  if  appropriate
anticoagulation  is  initiated  beforehand  [18].  Hence,  TEE-
guided  cardioversion  in  conjunction  with  anticoagulation  is
recommended  in  guidelines  for  the  treatment  of  persistent
AF  [11,13].
t
p
f
pThe  ACE  study  compared  the  LMWH  enoxaparin  with
FH  +  VKA  during  TEE-guided  or  conventional  cardioversion
nd  demonstrated  non-inferiority  of  enoxaparin  to  standard
are  with  UFH  +  VKA  for  preventing  thromboembolism  and
leeding  [7].  Because  LMWH  is  easier  to  administer  and  does
ot  need  frequent  monitoring,  currently  it  is  often  used  in
EE-guided  cardioversion.  However,  enoxaparin  has  to  be
iven  twice  daily  and  carries  a  small  but  potential  risk  of
hrombocytopoenia.
The  results  of  our  study  showed  a  very  low  combined  efﬁ-
acy/safety  event  rate  in  both  the  fondaparinux  (1.7%)  and
FH  +  VKA  (1.2%)  arms,  about  one-third  of  the  expected  rate
ased  on  the  rate  in  the  control  arm  of  the  ACE  study  [7].
ur  ﬁnding  of  a  low  event  rate  is  similar  to  that  in  other
tudies  investigating  the  value  of  TEE-guided  cardioversion.
he  Assessment  of  Cardioversion  Using  Transoesophageal
chocardiography  (ACUTE  II)  study,  which  included  155
atients  randomized  to  either  enoxaparin  or  UFH  +  VKA
6], reported  no  cases  of  embolism  or  major  bleeding.
he  Ludwigshafen  Observation  Cardioversion  Study  com-
rised  1076  consecutive  non-randomized  patients,  of  whom
19  underwent  TEE-guided  cardioversion  [19].  The  rate  of
hromboembolic  complications  was  very  low  (6/719;  0.8%),
s  was  major  bleeding  (2/719;  0.3%).  The  AFFECT  study,
hich  treated  162  patients  with  the  LMWH  certoparin,  only
eported  one  embolic  event  and  three  major  bleedings
20].
Interestingly,  embolism  and  bleeding  rates  were  much
igher  in  the  UFH  +  VKA  arm  in  the  ACE  study,  at  4.8%  [7].
 potential  explanation  for  this  difference  in  event  rates  is
he  fact  that  the  ACE  study  included  patients  who  underwent
EE-guided  cardioversion  as  well  as  patients  who  received
onventional  longer-term  treatment  with  anticoagulation.
nother  possible  explanation  could  be  the  strict  anticoagu-
ation  control  in  our  study.
Importantly,  our  study  underlines  the  safety  of  TEE-
uided  cardioversion  in  the  setting  of  effective  antico-
gulation.  A  further  relevant  ﬁnding  in  our  study  was
hat  we  did  not  observe  major  bleedings  in  clot-positive
atients  with  prolonged  treatment  of  therapeutic  doses  of
ondaparinux  (≥  4  weeks  of  therapeutic  doses  of  fonda-
arinux).
1f
t
a
a
e
e
a
w
i
l
t
m
t
C
I
p
t
b
D
A
n
B
G
I
s
D
G
e
G
P
a
n
A
T
g
t
s
o
i
t
K
d
P
r
A
P
F
P
E
A
G
L
M
D
G
P
b
B
K
t
(
(
(
(
I
S
A
E
F
G
I
G
G
C
H
D
C
A
D
w
W
D
R30  
The  mean  duration  of  hospitalization  was  shorter  in
ondaparinux-treated  patients  than  in  the  conventionally-
reated  patients.  This  was  mainly  due  to  the  need  for  more
nd  prolonged  anticoagulation  monitoring  in  the  UFH  +  VKA
rm.  Similar  results  were  reported  in  the  ACUTE  II  study  of
noxaparin  versus  UFH  [6].
The  most  important  limitation  of  our  study  is  the  low
vent  rate.  Hence,  direct  comparison  between  fondaparinux
nd  standard  care  is  not  statistically  feasible.  Nevertheless,
e  used  hard  endpoints  and  all  events  were  reviewed  by  an
ndependent  and  blinded  adjudication  committee.  A  central
aboratory  for  TEE  assessments  was  involved  in  the  study  but
he  results  obtained  did  not  inﬂuence  investigators’  treat-
ent  decisions.  In  addition,  completeness  and  readability  of
he  TEEs  were  limited  and  thus  were  not  described  in  detail.
onclusions
n  patients  with  TEE-guided  cardioversion,  the  use  of  fonda-
arinux  appeared  to  be  well  tolerated,  with  similar  efﬁcacy
o  UFH  +  VKA.  Furthermore,  a  trend  towards  greater  throm-
us  resolution  with  fondaparinux  was  observed.
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